The extent of cognitive deterioration after schizophrenia (SZ) onset is poorly understood because prior longitudinal studies used small samples of older individuals with established illness.
A lthough neuroimaging provides insight into brain changes associated with schizophrenia (SZ), the field has struggled with 2 questions. First, whether schizophrenia is a neurodevelopmental or a neurodegenerative disorder is unclear. Early [1] [2] [3] and more recent structural imaging studies [4] [5] [6] [7] [8] [9] showed increased ventricle size and reduced gray matter, supporting the concept of neurodegeneration introduced by Kraepelin and Robertson. 10,11 However, studies have not consistently shown neurodegeneration at the cellular level, 12,13 and some investigations suggest that a subset of changes in brain structure are associated with the effects of antipsychotic treatment. 14 Second, clarity about the influence of age at psychosis onset on subsequent cognitive development is lacking. Earlier onset has been associated with poorer cognition 31 and reduced gray matter volume, 32 but this association is not consistently reported when patients are age matched to control individuals. 33, 34 One longitudinal study in childhood-onset SZ showed normalization of cortical thinning in parietal regions, with continued reductions in frontal and temporal cortical thickness from late adolescence into early adulthood, leaving only the pattern of frontotemporal reductions that is typically observed in adult-onset SZ. 35 These findings suggest that early age at onset may be associated with a different pattern of disruption in brain structure and functioning than later-onset cases, serving as the basis of poor outcome in these individuals; however, lack of age-matched controls and/or comparisons of group means alone may obscure subtle age-related effects. Therefore, modeling dynamic changes in brain structure and function using functional magnetic resonance imaging (fMRI) during development to examine potential mechanisms that influence illness onset and course is critical. To our knowledge, the utility of fMRI in elucidating agerelated changes in brain function in SZ has not been fully explored. 36 Because structural and functional changes within the dorsolateral prefrontal cortex (DLPFC) are consistently replicated across all phases of SZ, 37,38 the DLPFC stands as a principal area worthy of developmental investigation. Previous fMRI studies demonstrated that changes in prefrontal activation during follow-up are associated with reductions in psychotic symptoms, 39,40 improved social functioning, 41 and treatment response. [42] [43] [44] [45] These studies examined small samples, short follow-up periods, and adult patients with chronic illness. Larger-scale longitudinal studies following up young individuals through the earliest phases of illnesscompared with age-matched healthy controls (HCs)-are needed to determine the age-related factors associated with early illness course and outcome. 46 Consequently, this study examined the association of age at psychosis onset and developmental changes across the age span with prefrontal activation and associated behavior in young individuals early in the course of SZ spectrum disorders and demographically matched HCs. Individuals ranged in age from 12 to 25 years, covering the typical window for psychosis onset and the associated critical period of prefrontal brain development from adolescence into young adulthood. We used fMRI, an established measure of DLPFC-related cognition (AX Continuous Performance Task [AX-CPT] 47-52 ), and mixed-effects models 53 to investigate the longitudinal pattern of prefrontal activation and behavior during a 2-year follow-up within and between the 2 groups. Attrition is common in large-scale longitudinal studies, and our proposed statistical approach based on random effects capitalizes on all available data, including individuals with and without follow-up. This investigation examines (1) the association of age with prefrontal cognitive dysfunction present at baseline in SZ and (2) whether deterioration occurs across the age span. At baseline, we hypothesized that patients with SZ would show worse performance (as captured by d′-context on the AX-CPT) and reduced PFC activation under conditions of high cognitive control compared with age-matched HCs but that younger age at onset would not be associated with increased impairment.
33,34
Based on previous findings, 22,29,30 patients with SZ were not hypothesized to show deterioration in performance and brain activity across the age span, demonstrating that prefrontal functioning is already impaired at psychosis onset and does not deteriorate further. Based on findings from Lesh et al, 15 the association with use of antipsychotics was examined. Antipsychotic treatment was hypothesized to be associated with higher performance and prefrontal activity across the age span. Exploratory analyses examined the influence of time since baseline, sex, duration of untreated psychosis, symptoms, and global functioning on performance and brain activation within the SZ group.
Key Points
Question Do young patients with recent-onset schizophrenia show a pattern of improvement or deterioration of prefrontal cognitive control processes during the first 2 years after illness onset compared with age-matched healthy controls?
Findings In this naturalistic, longitudinal, functional magnetic resonance imaging study, 87 young patients early in the course of schizophrenia showed stable behavioral and functional deficits in cognitive control that paralleled the pattern of 93 age-matched healthy control individuals across the age span.
Meaning
In support of the neurodevelopmental hypothesis of schizophrenia, no evidence was found of (1) differential impairment related to earlier age at onset or (2) deterioration of cognitive control processes in young patients with recent-onset schizophrenia. 
Methods

Participants
AX Continuous Performance Task
Participants completed the AX-CPT during fMRI ( Figure 1 and eMethods in the Supplement). Performance on the AX-CPT was measured using d′-context as Z AX hits (percentage correct) minus Z BX false alarms (percentage of errors), 60 which indexes the ability to use context to correctly respond to X probe in the context of a specific cue (A or B type).
Functional Imaging Methods and Data Analysis
Participants performed 4 blocks of event-related fMRI using the AX-CPT following the parameters in Figure 1 (eMethods in the Supplement). Data were collected on a 1.5-T scanner with a custom head coil (GE Healthcare). Functional MRI data were analyzed with Statistical Parametric Mapping-8 software (SPM8) (https://www.fil.ion.ucl.ac.uk/spm/software/spm8) and the FMRIB Linear Image Registration Tool 61,62 using all available scans. At baseline, whole-brain group-level randomeffects analyses were conducted for the cue B minus cue A contrast (representative of high vs low cognitive demand), with a voxelwise threshold of P < .001 and cluster correction for false discovery rate set at P < .05. In addition to baseline whole-brain analyses, a priori left and right DLPFC regions of interest (ROIs) associated with goal maintenance were selected for longitudinal analyses.
63,64
To model changes in brain activity across time, we extracted β values for each participant from the a priori ROIs for cue B minus cue A contrasts at each point. These ROI measures were used as described below to examine longitudinal changes.
Statistical Analysis
Data were analyzed from April 15, 2015, through August 29, 2017. Baseline group differences were assessed using 2-sample t tests for continuous variables and χ 2 tests (or Fisher exact tests when appropriate) for categorical variables. Mixed-effects linear models 53 were used to characterize the longitudinal trajectories of behavioral performance and blood oxygenation level-dependent signal and assess their associations with group and covariates. This approach is appropriate for repeatedmeasures data and accommodates missing and unequally spaced observations. Therefore, individuals with baseline information, as well as those with baseline and follow-up assessments, contributed data for the analyses. For each dependent variable, we first fitted a model to describe the course for HCs, with the linear and quadratic effect of age (centered at the mean age in the sample, 19.2 years) as fixed effects and a random effect for individual to account for the correlation due to repeated measures on the same individual. We removed the quadratic age effect if it was not significant. To this base model, we added and tested terms for group (SZ and HC) and its interaction with the linear and quadratic effect of age (where applicable) to examine group differences in the trajectories across the age span. Terms were retained if they added significantly to the core model. To evaluate whether time-varying characteristics, such as time since baseline, duration of untreated psychosis, clinical symptoms, global functioning, and antipsychotic use, were associated with the dependent variables, we tested each one individually by adding them to the core models as interactions with group. We Target response is an X, but only when it follows an A Response:
Trial Type AX, 70%; AY, 10%; BX, 12.5%; and BY, 7.5%
Individuals make a target response to probe X only when it follows the cue A. Nontarget BX trials require increased cognitive control to prevent error.
Research Original Investigation
Longitudinal Functional Magnetic Resonance Imaging of Prefrontal Function After Onset of Schizophrenia also investigated the effects of sex by adding a corresponding fixed effect in the model. Additional sensitivity analyses were conducted restricting the sample to the participants with at least 1 follow-up visit to confirm the longitudinal pattern from the primary analyses. Tests for all a priori hypotheses and exploratory analyses of clinical factors were 2-sided, with P < .05 considered statistically significant. All analyses were implemented using the PROC MIXED program in SAS software, version 9.4 (SAS Institute Inc).
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Results
Demographic characteristics are presented in Table 2 reports results of the mixed-effects models for behavioral performance and brain activation and for the effect of medication in the SZ group. eTables 2 to 4 in the Supplement report the exploratory results of the mixed-effects models examining the effect of covariates (sex, time since baseline, duration of untreated psychosis, clinical symptoms, and global functioning) on performance and activation in the SZ group.
Performance
As illustrated in Table 2 and Figure 2A , the model for behavioral performance (d′-context) included terms for linear and quadratic effects of age and group. The interaction terms for group with linear and quadratic age effects were not significant and therefore removed from the model, suggesting that the SZ group paralleled the pattern of performance of the HC group across the age span. The fixed effect for group was significant, indicating that the SZ group performed more poorly than controls across the age span (estimated difference [SE], −0.571 [0.12]; P < .001).
The association with medication use is summarized in Table 2 and Figure 2B . The SZ group not receiving medica- 
Functional Activity
At baseline, whole-brain analysis revealed reduced activation bilaterally in the PFC-parietal cognitive control network under conditions of high cognitive control (cueB−A)inpatients with SZ when compared with HCs of similar age ( Figure 3A) . Analyses using the a priori left DLPFC ROI showed lower blood oxygenation level-dependent activation in the SZ group for high control trials relative to the HC group (cue B − A Table 2) . No change in activation with age and no group by age interaction was observed on the left side (shown in Figure 3B ). for the SZ group; P = .003) with no effect of age were also observed in the right DLPFC ROI ( Figure 3C ). The medicated SZ group showed higher activation than the nonmedicated SZ group, but this difference did not reach significance. A similar pattern was observed in the right DLPFC. The nonmedicated and medicated SZ groups showed lower activation than the HC group on high control trials (nonmedicated SZ group, −0.83; medicated SZ group, −0.37 from HCs; both P < .05). The medicated SZ group showed higher activation than the nonmedicated SZ group, but this difference did not reach significance. .007]; P = .01) were associated with significantly lower performance on the AX-CPT, regardless of age (eTable 2 in the Supplement; all P < .05). Clinical factors, however, did not affect the trajectory of performance or activation across the age span.
Exploratory Analysis of Covariates
The SZ group with follow-up contributed data to estimates of the effect of time since baseline on cognitive control performance and associated activation. Although time in the study did not reach statistical significance as a covariate (except for left DLPFC ROI activation), all coefficients were positive, suggesting that performance did not worsen over time in patients with SZ and follow-up data (eTables 2 to 4 in the Supplement). eTable 5 in the Supplement reports results of sensitivity analyses restricted to the 90 participants with at least 1 follow-up. Results parallel those from the core models, with the estimates of effect of time since baseline in the SZ group close to 0 (d′-context) or positive (DLPFC ROI activation), although relatively small with respect to SEs.
Discussion
To our knowledge, this study is the first to examine the longitudinal course of behavioral and functional deficits in cognitive control in young individuals with recent-onset SZ. Although typical cross-sectional studies only allow examination of age differences between groups, the current investigation used mixed-models analysis to examine (1) age-related differences between HCs and patients with SZ at baseline and (2) differences in the pattern of age-related changes within and between HCs and patients with SZ over time. In this large sample, deficits in cognitive control were observed in the SZ group relative to agematched HCs at baseline using a well-validated paradigm, the AX-CPT. [47] [48] [49] [50] [51] [52] We found no evidence for longitudinal deterioration of PFC functioning; rather, patients and HCs exhibited similar developmental trends in behavioral performance and brain function throughout adolescence and early adulthood.
Performance
Individuals with SZ showed impairments in cognitive control at illness onset regardless of age. This finding is consistent with previous behavioral studies of first-episode psychosis, 51 including those in the present cohort. 15,26,52,54,55 Onset of SZ coincides with critical periods of brain development during adolescence and early adulthood, 9 and cognitive functioning in healthy young adults improves during adolescence and early adulthood. Age at onset, however, was not associated with the extent of impaired behavioral performance in the SZ group because they showed a stable deficit at the point of onset, with a pattern of performance during follow-up that was comparable to that of the HCs.
Functional Activity
Consistent with previous studies, 15,26,38,52,54,55 patients exhibited significantly lower bilateral DLPFC activation during cognitive control-associated trials compared with the HCs. Paralleling our behavioral results, comparable DLPFC deficits were observed regardless of age at onset, and patients showed reduced yet stable bilateral DLPFC activation across the developmental age similar to that of the HCs. This finding supports the neurodevelopmental hypothesis of SZ, 16, 17 in which deficits emerge before illness onset and remain relatively stable. Behavioral and functional activation results suggest prefrontal development is not arrested in SZ but rather that patients show ongoing brain development comparable to that of HCs, highlighting the possibility for plasticity and developmental capacity with therapeutic implications.
Association of Antipsychotic Medication
Individuals with SZ who were using antipsychotics at the time of assessment showed a tendency toward better performance than those who used no medication. Across the age span, the medicated SZ group showed greater left DLPFC activation compared with the nonmedicated SZ group. Consistent with previous studies, 66 medications did not account for the cognitive deficits observed in this SZ sample. Although consistent with previous publications, 15 we must acknowledge that our nonmedicated SZ group was small, and we did not examine the association of within-individual changes in medication dose between assessments or adherence owing to the naturalistic nature of the study. Therefore, these results should be considered preliminary and in need of replication.
Exploratory Analysis of Covariates
Neither sex nor duration of untreated psychosis was associated with performance or DLPFC activation, on average, across the age span. Symptom severity and poor global functioning were associated with worse cognitive control. These findings suggest that the clinical and functional state may be associated with an individual's mean prefrontal functioning but are not associated with their pattern of recovery or deterioration during follow-up. These results also suggest that pathologic changes in SZ may not affect the development of cognitive control processes after illness onset.
Limitations
This work is strengthened by inclusion of task-based functional neuroimaging analysis, bolstering links between brain and behavior in an established cognitive deficit in SZ. Longitudinal studies of the neuronal basis of cognition in psychiatric diseases are rare owing to the inherent challenges in performing such studies. Although this study was strengthened by the large sample size at baseline, significantly higher attrition was observed in the SZ compared with the HC groups, which may bias results. Our mixed-effects analysis yields valid estimates under the assumption of data missing at random, and valid estimates of group effects can often be obtained even when missing values are not completely random. 67 We conservatively estimated the association of time since baseline using only the patients with SZ with follow-up data. A second potential limitation is practice effects; however, a longitudinal study of AX-CPT performance 68 did not report practice effects in younger patients with SZ. In general, this study was a treatment-engaged cohort with most participants showing clinical improvement during the relatively short follow-up period. These results might not generalize to a community-based sample or over a longerterm follow-up period. Future replication studies with additional follow-up are important next steps.
Conclusions
Results suggest that cognitive control deficits in SZ are present at onset and nondeteriorating, in agreement with the neurodevelopmental model of illness. Indeed, the observed pattern of performance for SZ across the age span suggests that these patients continue to benefit from ongoing brain maturation during the critical period of development from adolescence into young adulthood. Future research should examine the effects of specific interventions (eg, cognitive remediation, psychotherapy, medication, supported education, and employment) on the trajectory of cognitive control deficits in psychotic illness. 3 ). Diagnoses were case conferenced after 6 months using all available research and clinical information to confirm schizophrenia spectrum diagnosis and inclusion in the study. A small proportion of individuals were considered to meet criteria for DSM-IV Schizophreniform disorder at case conference if they demonstrated full remission of Criterion A symptoms within 6 months, and maintained symptom remission after medication discontinuation when followed over a subsequent 6 months.
HC participants did not meet criteria for any Axis I diagnosis, denied current substance abuse or any substance dependence, and were not taking any psychotropic Using SPM8, standard preprocessing steps included slice timing correction and realignment using SPM8. The functional data was coregistered to each individual subjects' structural image using FLIRT. FLIRT was implemented for the coregistration step due to noticeably improved EPI to T1 alignment compared to the SPM8 variant, which may be related to partial brain coverage in some EPIs. Individual subject structural images were segmented in SPM8 and the gray matter image was used to normalize each individual subject T1 to the SPM8 gray matter MNI template. Lastly, spatial smoothing was performed using an 8mm FWHM kernel. Individual fMRI runs were excluded from the analysis if translational movement exceeded 4 mm or if rotational movement exceeded 3° within a run. Each subject had to retain at least two or more runs in order to be included in the final analyses. Task regressors consisted of correct trials for both cue types (A and B) and all probe combinations (AX, AY, BX, and BY), which were entered into a general linear model (GLM). Additionally, translational and rotational movement parameters were included as covariates in each individual subject GLM. 
